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 ABBREVIATIONS 
 
A: adenine 
ACC: acetyl-CoA carboxylase 
AMP: adenosine monophosphate 
AMPK : adenosine monophosphate activated 
protein kinase 
ALAT: alanine aminotransferase 
ASAT: aspartate aminotransferase 
BCAA : branched-chain amino acid 
C: cytosine 
CBF: CCAAT box binding factor 
cDNA: complementary DNA 
Co: control 
CPT1 : carnitine palmitoyltransferase 1 
ddNTP: dideoxynucleoside triphosphate 
dNTP: deoxynucleotids triphosphate 
EDTA : ethylene-diamine-tetra-acetic acid 
EER: estrogen related receptor 
FA : fatty acid 
FFA : free fatty acid 
Fox01: forkhead transcription factor 
G: guanine 
GH: growth hormone 
GR: glucocorticoid receptor 
GRE: glucocorticoid response element 
GRU: glucocorticoid response unit 
IGF-1: insuline-like growth factor 1 
IGFBP-3: insuline-like growth-factor binding 
protein 3 
IKH : idiopathic ketotic hypoglycemia 
 
kbp: kilo base pair 
MAPK: mitogen-activated protein kinase 
mRNA: messenger RNA 
PCR: polymerase chain reaction 
PDC : pyruvate dehydrogenase complex 
PDK : pyruvate dehydrogenase kinase 
PDK2: pyruvate dehydrogenase kinase 
isoenzyme 2 
PDK4 : pyruvate dehydrogenase kinase 
isoenzyme 4 
PDP: pyruvate dehydrogenase phosphatase 
PGC-1 peroxisome proliferator activated 
receptor  coactivator 
PPAR: peroxisomal proliferator-activated 
receptor 
PRL: prolactin 
RA: retinoic acids 
RAR : retinoic acid receptor 
RARE: retinoic acid response element 
Rb: retinoblastoma 
RT: reverse transcriptase 
RXR : retinoid X receptor  
T: thymidine 
T3 : thyroid hormone 
TBE: tris-borate 
TCA : tricarboxylic acid 
TR: thyroid hormone receptor 
TRE: T3-response element 
TSA : trichostatin A 
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1. INTRODUCTION 
 
1.1. Idiopathic Ketotic Hypoglycemia 
 
Idiopathic ketotic hypoglycemia (IKH) is the most common cause of hypoglycemia in childhood, 
among non-diabetic children (1). IKH is defined by episodes of hypoglycemia with high ketone 
levels in plasma and urine, provoked by periods of fasting, often in combination with an 
intercurrent illness (2). IKH usually begins between 18 months and 5 years of age (3) and typically 
spontaneously remits by the age of 8 or 9 (2). Patients with IKH are predominantly male. They are 
often less than 50th percentile for height and weight (3).  
 
The most common symptom leading to evaluation in an emergency department is lethargy, 
expressed as sleepiness, fatigue, decreased energy, or inability to awake normally from sleep. 
Vomiting is also a frequent symptom. Some patients even present with a first seizure (1). 
Symptoms of hypoglycemia can be divided in two categories: neurovegetative and 
neuroglycopenic symptoms (4). 
The autonomic response causes the early symptoms of hypoglycemia, which include sweating, 
weakness, tachycardia, pallor, nausea, vomiting, tremor, nervosity and hunger. These symptoms 
usually occur at higher blood glucose concentrations than the symptoms of neuroglycopenia (4). 
The neuroglycopenic symptoms result from brain glucose deprivation. They are more severe than 
autonomic symptoms and usually start at lower blood glucose levels, when hypoglycemia occurs 
rapidly and/or is prolonged in time. These symptoms include lethargy, irritability, confusion, 
uncharacteristic behavior, hypothermia, hypotonia, headache, visual troubles, dysarthria, aphasia, 
hemiplegia, paresthesia, amnesia, dizziness, seizure and coma (4).  
However, neuroyglycopenic symptoms can occur without a warning autonomic response after 
repeated or prolonged episodes of hypoglycemia, when the threshold of neurovegetative 
symptoms is decreased to that for neuroglycopenic signs. Permanent central nervous system 
damage and even death can occur due to severe and repeated episodes of hypoglycemia (4). 
The symptoms usually appear in the morning, after a fasting period of 10-20h (1,3). The diagnosis 
of IKH can be difficult because the symptoms and clinical signs are unspecific (3). 
Hypoglycemia due to IKH improves after oral or intravenous glucose administration (5). Dietary 
interventions to prevent new episodes include avoiding fasting, frequent snacks and meals rich in 
complex carbohydrates (3). 
 
The pathophysiology of IKH has not been fully understood. Investigations have searched for 
disturbances in gluconeogenesis, glycolysis, glycogenolysis, regulation of insulin response to 
fasting states and brain glucose utilization (1).  
Children with IKH only present symptoms after a relatively long fasting period. This suggests that 
their glycogenolysis pathway is intact. Moreover, these patients have a normal response to 
glucagon in the fed state and patients with IKH do not have inappropriately increased insulin levels 
in the starved state (1), thus excluding hyperinsulinism as a pathogenic mechanism. 
Endogenous glucose production is decreased in IKH: glycogenolysis decreases physiologically 
without the expected compensatory increase in gluconeogenesis, despite all hormonal stimuli to 
gluconeogenesis are activated. However the gluconeogenic pathway has been proven to be intact. 
Thus, an adequate glycemic response following administration of gluconeogenic precursors can be 
observed. It has been shown that IKH patients have lower alanine levels, which implicates a 
substrate deficiency for gluconeogenesis as a factor in the pathophysiology of IKH. Alanine 
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production may be limited in IKH (2). Alanine sources may be limited in certain children, perhaps 
because of a lean body mass. This could explain why the disorder remits with age and growth 
(1,2). 
Young children have a higher brain mass to body mass ratio and cerebral glucose utilization is the 
major contributor to peripheral glucose uptake. Therefore, there is a relatively high glucose 
demand and hepatic glycogen is more rapidly depleted during fasting, increasing the dependency 
in gluconeogenesis. This could explain the spontaneous remission of IKH with increasing age (2). 
Fatty acid (FA) mobilization has an important role in the maintenance of glucose homeostasis. Free 
fatty acids (FFAs) and ketone bodies can be used by body tissues and reduce their demands for 
glucose. However, the brain cannot use FFAs directly because they do not cross the blood-brain 
barrier. It can only use ketone bodies to partially replace glucose. Ketone bodies are derived from 
oxidation of leucine among other amino acids or fatty acids (4). In a study, data have shown a 
lower leucine oxidation in IKH children, while energy expenditure is significantly increased. This 
may be of pathophysiological relevance. Impaired ketone body utilization seems unlikely because 
neither extreme supra-physiological levels of plasma ketone bodies nor an increased peripheral 
glucose uptake have been found (5). 
Some authors even postulate that IKH is not a true disease but represents the lower tail of the 
Gaussian distribution of fasting tolerance in children (1,2). However, familial recurrence of IKH is 
often observed, suggesting a genetic basis of glucose homeostasis dysregulation. 
 
 
Figure 1: Substrates utilization during fasting 
 
The hypothesis of this Master project is that variations in genes involved in the glucose 
homeostasis could be the cause of IKH. In this study, we have a particular interest for the pyruvate 
dehydrogenase kinase isoenzyme 4 (PDK4) gene (ENST00000005178), located on chromosome 
7q21.3 (6). 
 
1.2. Pyruvate Dehydrogenase Kinase 4 
 
The mitochondrial pyruvate dehydrogenase complex (PDC) catalyses the conversion of pyruvate to 
acetyl-CoA, linking the glycolytic degradation of glucose and the degradation of glycogen to the 
tricarboxylic acid (TCA) cycle. The result of this reaction is the loss of glucose carbon as CO2 and 
the generation of NADH (7–9).  
The entry of acetyl-CoA into the TCA cycle allows ATP generation from glucose. The combination 
of acetyl-CoA with oxaloacetate produces citrate, which enters the TCA cycle. Citrate exits the 
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mitochondrion and is then cleaved to yield cytoplasmic acetyl-CoA, which is converted in malonyl-
CoA. Malonyl-CoA serves as precursor for FA synthesis. Malonyl-CoA is also an inhibitor of 
carnitine palmitoyltransferase 1 (CPT1), required for the import of acyl-CoAs derived from FA into 
mitochondria. Therefore, increased rates of glucose utilization block FA oxidation (7,9) and ketone 
bodies production. 
The conversion of pyruvate into acetyl-CoA is irreversible, therefore inhibition of PDC is crucial to 
conserve glucose when glucose supply is insufficient (7–9).  
 
 
 
Figure 2: PDK4, PDC and interlinking metabolic pathways 
 
The regulation of PDC includes three mechanisms: 1) the reversible phoshorylation or 
dephosphorylation of PDC, 2) levels of acetyl-CoA and NADH and 3) the transcriptional regulation 
of the regulatory enzymes. (7,9) 
Short-term regulation of PDC involves the pyruvate dehydrogenase kinases (PDKs), which 
phosphorylate and inactivate the PDC, and the pyruvate dehydrogenase phosphatases (PDPs), 
which dephosphorylate and activate the PDC. During starvation, the PDC is inactivated to maintain 
glucose levels by conserving substrate for gluconeogenesis (7–10). 
 
The PDC is composed of multiple copies of three subunits: E1 - pyruvate dehydrogenase, E2 – 
dihydrolipoamide acetyltransferase and E3 – dihydrolipoamide dehydrogenase. E1 catalyses the 
conversion of pyruvate into acetyl-CoA and is regulated by PDKs and PDPs. Each PDC contains two 
or three PDK molecules bound to E2. The phosphorylation can occur subsequently at three 
different sites on E1: serine 293 – site1, serine 300 – site2 and serine 232 – site 3. Phosphorylation 
of one site is sufficient to inactivate the PDC. Site 1 phosphorylation is the most rapid and site 3 
phosphorylation is the slowest (7,9). 
 
PDK4 as candidate gene for IKH 
 
The present knowledge about the regulation of PDC, the central enzyme in energy metabolism 
homeostasis, in human and animal models, points to PDK4 as an important player in glucose 
homeostasis during fasting. Here in summary the main reasons for which we have we have chosen 
PDK4 as candidate gene for IKH: 
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Tissue expression of PDK4 indicates that this isoform is active in the main tissues involved in 
glucose homeostasis. 
Four PDK isoforms have been identified: PDK1, PDK2, PDK3 and PDK4. PDK1 can be found in heart, 
pancreatic islets and possibly skeletal muscle. PDK2 is expressed ubiquitously, with high 
expression in the heart, liver and kidneys. PDK3 is detected in the testis, kidneys and brain. PDK4 is 
found in the heart, skeletal muscle, the liver, kidneys and the pancreatic islets. All tissues in which 
PDK4 is expressed are involved in glucose homeostasis: high rates of glucose utilization, glucose 
production or production of glucoregulatory hormones (7,9). 
 
PDK4 phosphorylates all three phosphorylation sites of PDC, whereas other PDK isoformes act only 
on two of them. 
All four PDKs phophorylate site 1 and 2, but only PDK1 phosphorylates site 3. Moreover, PDK4 
shows a higher activity towards site 2 compared with PDK1, PDK2 and PDK3 (9).  
Thus, PDK2 may account for short-term inhibition of PDC through phosphorylation of site 1, 
whereas PDK1 and PDK4 may be more important for allowing multisite phosphorylation, which 
has been postulated to retard reactivation of PDC by PDP (7). 
 
Low intracellular glucose availability promotes PDK4 expression. 
Acetyl-CoA and NADH directly inhibit the PDC and indirectly promote inactivation of PDC by 
stimulation of PDK activity. Pyruvate is an inhibitor of PDK activity.  
These short-term mechanisms are supplemented by a long-term regulation consisting in a stable 
increase of PDK activity due to an increased expression of PDK genes. 
 
Starvation and diabetes increase the amount of PDK isoenzyme 4 in rat heart. The amount of PDK4 
is important in long-term regulation of the pyruvate dehydrogenase complex in rat heart. It has 
been shown that the increase in the amount of rat heart PDK4 protein correlates with the stable 
increase in PDK activity that occurs in the heart of starved and diabetic rats. Furthermore, 
starvation and diabetes induce a PDK isoenzyme shift in rat heart: PDK4 increased from less than 
one-third of the total PDK protein to more than 50% in the starved state and to 75% in the diabetic 
state. Therefore, it seems that PDK4 protein may contribute more than any other PDK to the 
increase of PDK activity. This suggests that an increase in the amount of PDK activity caused by an 
increase in the amount of PDK4 protein leads to greater phosphorylation and lower activity of the 
PDC. This suppresses glucose oxidation and favors FA oxidation in the heart of starved and diabetic 
rats in order to spare glucose, which is advantageous in the starved state but exacerbates the 
diabetic state because glucose is spared instead of being oxidized to face high levels of glucose in 
blood (11). 
 
PDK4 knockout mice have fasting relative hypoglycemia because of inappropriately high flow of 
glucose through PDC. 
Studies have shown that blood glucose levels are lower in PDK4-/- mice than in wild type after 
starvation. This suggests that PDK4 is important to maintain a normal glycemia during fasting.  
In the liver of starved PDK4-/- mice, the concentration of intermediates of the gluconeogenic 
pathway are lower, which is consistent with a lower rate of gluconeogenesis due to lack of 
substrates. The induction of a lower concentration of precursors is a consequence of higher PDC 
activity in PDK4-/- mice. In mice lacking in PDK4, concentrations of lactate, pyruvate and alanine 
are lower because oxidation of pyruvate is stimulated. The decreased pyruvate availability inhibits 
transamination of branched-chain amino acids (BCAAs), which are a source of amino groups for 
alanine formation. This results in an elevation in BCAAs and a reduction in alanine.  
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Starvation induces a greater increase in non-esterified FA and ketone bodies in PDK4-/- mice. But it 
is not known whether this is due to a greater hepatic ketogenesis or less ketone body utilization by 
peripheral tissues (10). 
 
Low energy status induces PDK4 expression either through AMP sensing or through free fatty acid 
and PPAR-  signaling. 
Adenosine monophosphate activated protein kinase (AMPK) and FA synergistically induce PDK4 
expression and decrease cellular glucose oxidation at the same time. Adenosine monophosphate 
(AMP), which is a signal for low energy status, activates the AMPK. Activated AMPK 
phosphorylates acetyl-CoA carboxylase (ACC), which converts acetyl-CoA in malonyl-CoA. Malonyl-
CoA is an inhibitor of CPT1, required for the import of acyl-CoAs into mitochondria. AMPK 
activation relieves repression of CPT1 by malonyl-CoA by phosphorylation and inactivation of ACC 
and so increases energy production by FA oxidation. AMPK and FA play a role in the energy 
homeostasis by sparing glucose (12). 
 
FFAs can activate the peroxisomal proliferator-activated receptor (PPAR)- and activation of 
PPAR- can enhance PDK4 expression. Starvation can increase PDK4 expression in tissues of wild-
type mice but not in PPAR- -/- mice. This indicates the importance of PPAR- for PDK4 expression 
during starvation (13). 
 
Hormonal control of PDK4 expression: PDK4 is up-regulated by contro-insular hormones and 
thyroid hormones. 
Exercise, fasting and epinephrine increase PDK4 messenger RNA (mRNA) expression in epididymal 
adipose tissue. In contrast to PDK4, PDK1, 2 and 3 are not responsive to these perturbations. The 
phosphorylation of the PDC on serine 293 and 300 is also increased, which suggests an increase in 
PDK4 activity, since PDK4 phosphorylates these residues. Treatment with epinephrine increases 
PDK4 mRNA levels. Studies suggest that p38 mitogen-activated protein kinase (MAPK) and PPAR-  
may be involved in this pathway (14).  
 
Prolactin (PRL) and growth hormone (GH) can induce the expression of PDK4 in 3T3-L1 adipocytes. 
This effect is mediated by a STAT5 binding site in a hormone sensitive region in the murine PDK4 
promoter. PRL and GH potently activate STAT5 proteins. Moreover, insulin pretreatment 
attenuates the ability of these hormones to induce PDK4 expression (15).  
 
Transcription of the PDK4 gene is elevated by glucocorticoids and inhibited by insulin. This is 
mediated by the glucocorticoid receptor (GR). The GR binds to glucocorticoid response elements 
(GREs) within the gene and interacts with other transcription factors and coactivators to form 
glucocorticoid response units (GRUs), which control the gene expression. Studies have identified 
two distal GREs in the PDK4 promoter that are located more than 6000 base pairs 5’ to the start 
site of transcription. Subtle changes in the GRE alter transcriptional activation. Studies have also 
shown that forkhead transcription factor (Fox01) participates in the glucocorticoid induction of 
PDK4. Fox01 binding sites have been identified in the PDK4 promoters of mouse, human and rat.  
Insulin acts at multiple sites in the promoter to decrease PDK4 transcription. The GR and Fox01 are 
dissociated from the PDK4 promoter by insulin. Moreover, mutation of the 3’ estrogen related 
receptor (ERR) site reduces the ability of insulin to inhibit PDK4 transcription. This suggests that 
EER contributes to the insulin inhibition of PDK4 (16). 
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ERR  and ERR  are orphan nuclear receptors which have a role in the induction of fatty acid 
oxidation in heart and muscle. Both ERRs stimulate the PDK4 gene in hepatoma cells and recruit 
peroxisome proliferator activated receptor  coactivator (PGC-1  to the PDKs promoter. FoxO1 
binds to the promoter of PDK4 and contributes to its induction by ERRs and PGC-1 . Insulin 
suppresses PDK4 expression through the dissociation of FoxO1 and PGC-1  from the PDK4 
promoter (17). 
 
Recent studies demonstrate that thyroid hormone (T3) stimulates PDK4 gene expression in vitro in 
hepatoma cells and in vivo in hyperthyroid rats, via the thyroid hormone receptor (TR). TRs are 
nuclear hormone receptors, which are a class of ligand-activated transcriptional regulators. TRs 
bind to specific DNA sequences called T3-response elements (TRE). Two binding sites for thyroid 
hormone receptor have been identified in the promoter of the rat PDK4. Mutations of TRE reduce 
the ability of T3 to induce the PDK4 gene. It has also been shown that the PGC-1  plays an 
important role in the T3 stimulation of PDK4 expression. After T3 administration, there is an 
increase in the association of PGC-1  with the proximal rat PDK4 promoter, through interactions 
with the orphan nuclear receptor- ERR . This results from an increase in the abudance of the PGC-
1  by T3(18). 
 
Other transcriptional regulators of PDK4. 
Retinoic acids (RA) and Trichostatin A (TSA), an inhibitor of histone deacetylase regulate PDK4 
gene expression. Retinoid X receptor  (RXR ) and retinoic acid receptor  (RAR ) bind to and 
activate two retinoic acid response elements (RAREs). The two RAREs are present in the human 
PDK4 proximal promoter. Sp1, a transcription factor, and CCAAT box binding factor (CBF) bind to 
the region between two RAREs. Mutation of Sp1 or the CBF site decreases basal expression, 
transactivation by RXRa/RARa/RA, and the ability of TSA to stimulate PDK4 gene transcription (19). 
 
E2F1 is a transcription factor. It controls the cell cycle by promoting cellular growth during S phase. 
E2F1 is a component of the retinoblastoma (Rb)-E2F tumor suppressor complex. The Rb tumor 
suppressor binds E2F1 and represses its activity. A study demonstrates that E2F1 regulates the 
gene encoding PDK4, which is chronically elevated in obesity and diabetes and induced by 
starvation. It has shown that loss of E2F1 in mice results in lower blood glucose, improved plasma 
lipid profile and increased sensitivity to insulin stimulation. Inactivation of Rb induces PDK4 and 
increases the E2F1 occupancy onto the PDK4 promoter. Two overlapping E2F binding sites have 
been identified on this promoter. When E2F sites are mutated, the PDK4 promoter does not 
response to E2F1 (20). 
 
Conclusion 
All the above mentioned studies show that PDK4 has an important role in glucose homeostasis 
during starvation and point to this enzyme as a key regulator of fasting tolerance. From the 
present knowledge on PDK4, we hypothesized that genetic variations reducing PDK4 activity, could 
be disease-causing in some IKH patients.  
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2. METHODS 
 
2.1. Review of the medical records of IKH patients  
 
Clinical features 
The medical records of ten IKH patients were reviewed. Patients’ characteristics taken into 
account were: 
- sex 
- age of onset 
- weight and height 
- diet, nutritional habits 
- triggers of hypoglycemic crises 
- symptoms 
- presence/absence of hepatomegaly 
- psychomotor development 
 
Biochemical features 
The biochemical features chosen are those that are important for the differential diagnosis of 
hypoglycemia. They allow the identification of the cause of hypoglycemia.  
We characterized the episodes of IKH of each patient according to the following biochemical 
criteria: 
1. plasma glucose level 
2. plasma lactate, pyruvate, lactate/pyruvate ratio 
3. plasma keton bodies and urine strip tests  
4. serum free fatty acid  
5. plasma amino acid concentrations (alanine level, branched-chain amino acid levels) 
6. plasma free carnitine and acylcarnitine levels, acylcarnitine profile 
7. plasma transaminase levels 
8. cortisol, insulin, IGF1, IGFBP-3 
9. urinary organic acids 
 
Ad 1) Blood glucose concentrations were determined to define the degree of hypoglycemia. 
 
Ad 2) Pyruvate is the end product of the glycolysis. It can be converted to lactate, the end product 
of anaerobic glycolysis. Elevation of lactate level can indicate liver damage, impaired 
glycogenolysis or impaired gluconeogenesis. It is also elevated after a seizure or difficult blood 
sampling. Pyruvate is never measured without lactate. It is used to determine the lactate/pyruvate 
ratio, which is elevated in respiratory chain disorders (24). 
 
Ad 3) Ketosis is a physiological response to fasting (24). The ketone bodies include -
hydroxybutyrate, acetoacetate and acetone, but only -hydroxybutyrate and acetoacetate are 
transported in blood. FFAs are the precursors for ketogenesis in the liver, when glucose supply is 
lacking to form ATP (25). Urine test strips are used to detect and measure the level of ketone 
bodies in urine among other features of urine. Hypoglycemia associated with ketonuria suggests 
others diagnosis than hypoglycemia without ketonuria (24). 
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Ad 4) Elevation of FFAs suggests active lipolysis and that hypoglycemia is associated with fasting 
(24). 
 
Ad 5) Amino acids analyses in blood samples are helpful when disorders of energy metabolism or 
aminoacidopathy are suspected. Prolonged fasting induces increase of BCAA level leucine, 
isoleucine and valine (24).  
 
Ad 6) Carnitine allows the transport of long chain FAs in the mitochondrial matrix, where -
oxidation occurs. The long chain acyl-CoA is transformed in acylcarnitine and can go through the 
mitochondrial membranes (25). Free and total carnitine in plasma and acylcarnitine profile 
analysis are diagnostic tests for most fatty acids oxidation disorders, carnitine deficiency, carnitine 
transporter defect and various organic acidurias that could cause hypoglycemia. Generally, total 
carnitine values are normal, free carnitine values are decreased and acylbound carnitine values are 
increased after fasting (24). 
 
Ad 7) Alanine aminotransferase (ALAT) and aspartate aminotransferase (ASAT) tests were 
performed to detect a liver disease that may affect glucose homeostasis, FAs oxidation or 
ketogenesis. 
 
Ad 8) Cortisol, insulin, insuline-like growth factor 1 (IGF-1) and insuline-like growth-factor binding 
protein 3 (IGFBP-3) values were also assessed. Cortisol is a glucocorticoid hormone stimulating 
neoglucogenesis to reform glycogen so that the blood concentration of glucose can be maintained 
normal between meals by glycogen degradation. Insulin is a hormone promoting the storage of 
glucides, lipids and proteins. Their blood concentrations are then decreased (26). IGF-1 is a 
hormone whose structure is similar to insulin. It has its own receptor but it can also bind to insulin 
receptor. Actions of IGF-1 are then insulin-like. IGF-1 binds to IGFB-3. IGFB-3 increases half-life of 
IGF-1 and limits its availability. Fasting lowers IGF-1 level (27).  
 
Ad 9) Organic acids are analyzed in urine (24). They are derived from dietary protein, fat and 
carbohydrate and are used by the body to generate cellular energy. They are intermediary 
compounds of many biochemical pathways (28). Urinary organic acids test can detect inherited 
disorders of metabolism such as organic aciduria, aminoacidopathy, fatty acid oxidation defect 
and disorder of energy metabolism among others. A specific profile of urinary organic acids can 
suggest a particular metabolic disease (24). 
 
2.2.  Genetic analyses in IKH patients  
 
To study the PDK4 gene, we collected DNA samples from ten patients with previous episodes of 
IKH. Written informed consent was obtained from all participating individuals. The study has been 
approved by the ethics committee of the CHUV. 
 
The PDK4 gene is composed of 11 exons (6). The gene was divided into 11 fragments according to 
the size of the exons. Each fragment contains one exon with the following exeptions: Fragment 
4+5 contains exons 4 and 5, fragment 8+9 contains exons 8 and 9 and the huge exon 11 is divided 
in three fragments (11-1, 11-2, and 11-3). 
 
PCR-
Fragment 
1 2 3 4+5 6 7 8+9 10 11-1 11-2 11-3 
12 
Size (in bp) 1020 734 667 695 391 599 940 300 998 844 996 
 
The cDNA of PDK4 has a length of 1’236 bp. For RT-PCR the cDNA was devided into 3 fragments 
overlapping each other and allowing the sequencing of the whole cDNA in both directions. 
 
RT-PCR 
Fragment 
1 2 3 
Size (in bp) 900 960 900 
 
 
The following steps, explained below in detail, were applied for each patient and each fragment: 
 DNA extraction from EDTA blood 
 Primer design and preparation 
 Polymerase Chain Reaction (PCR) 
 Agarose gel electrophoresis 
 Purification of PCR product 
 Sequencing reaction (SR) 
 Purification of SR product 
 Sequencing on an ABI PRISM® 3100 Genetic Analyzer 
 Lecture and interpretation of sequencing results 
 
For patients the following steps were added: 
 RNA extraction from fibroblasts 
 Primer design and preparation 
 Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) 
 Agarose gel electrophoresis 
 purification of RT-PCR product 
 Sequencing reaction (SR) 
 Purification of SR product 
 Sequencing on an ABI PRISM® 3100 Genetic Analyzer 
 Lecture and interpretation of sequencing results 
 
2.2.1. DNA and RNA extraction 
 
DNA was extracted from leucocytes isolated from blood samples. Blood samples from the 10 IKH 
patients were taken in tubes with Ethylene-diamine-tetra-acetic acid (EDTA). EDTA prevents the 
blood from coagulation. RNA was extracted from fibroblasts of patients 1, 2, 3 and 6. Fibroblasts 
were obtained by skin biopsy and tissue culture. DNA and RNA were extracted with the AllPrep 
DNA/RNA Mini Kit from Qiagen.  
 
DNA extraction procedure: 
 
 The cells were lysed and homogenized in Buffer RLT. The Buffer RLT inactivates DNases and 
RNases so that intact DNA can be isolated. 
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 The lysate was transferred to an AllPrep DNA spin column placed in a collection tube. The 
lysate was passed through the AllPrep DNA spin column by centrifugation. The column and 
the high-salt buffer allow selective binding of DNA.  
 The column was then placed in a new collection tube and centrifugated. The spin column 
membrane was washed with Buffer AW1 and AW2. 
 The column was placed in a new collection tube and centrifugated. DNA was eluted with 
Buffer EB. 
 
RNA extraction procedure: 
 
 The cells were lysed and homogenized in Buffer RLT. The Buffer RLT inactivates DNases and 
RNases so that intact RNA can be isolated. 
 The lysate was transferred to an AllPrep DNA spin column placed in a collection tube. The 
lysate was then passed through the AllPrep DNA spin column by centrifugation. The 
column and the high-salt buffer allow selective binding of DNA. 
 Ethanol was added to the flow-through collected in the collection tube after the 
centrifugation. 
 The sample was transferred to an RNeasy spin column placed in a collection tube. The 
sample was passed through the RNeasy spin column by centrifugation. RNA binds 
selectively to the membrane of the column.  
 The column was placed in a new collection tube and centrifugated. The spin column 
membrane was washed with Buffer RPE. 
 The column was finally placed in a new collection tube and centrifugated. RNA was eluted 
with RNase free water. 
 
2.2.2. Primer design, order and preparation 
 
Primers are oligonucleotides that are complementary to sequences that flank the DNA segment of 
interest. The primer pairs are composed of a forward primer and a reverse primer. The forward 
primer is complementary to the 3’ end of the anti-sense strand of the DNA target, whereas the 
reverse primer is complementary to the 3’ end of the sense strand (21).  
 
The PCR primers were designed with the free software Primer3 
(http://frodo.wi.mit.edu/primer3/). Primers were ordered from Microsynth, Switzerland.  
 
The lyophilized primers delivered by Microsynth were hydrated with H2O MilliQ in order to obtain 
a stock solution with a concentration of 1 g/ l. The stock solutions are conserved at a 
temperature of -20oC. To prepare 100 l of working solution at a final concentration of 50 ng/ l, 5 
l of the stock solution were added to 95 l of H2O MilliQ. The primers sequences used for the PCR 
or RT-PCR are listed in the following tables. 
 
Primers for the PCR 
 
Fragment Primer name 
F=forward 
Primer Sequence 
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R=reverse 
1 1F GTT CTT CCC ACC CTT TTT CC 
 1R GAG CCT AGC CCT CCC TCT AC 
2 2F AAT CGC CCC TGA ATT ATC G 
 2R CAT TCA GAT CAC CTG TTT TCC A 
3 3F TGA ACA TAA TGC TTA CTT TCT CTT TTC 
 3R TTC AGA GCT GAA TTC CTT TAA TTT 
4+5 4+5F TGT TCA GAT GGG TAA TGC AAA 
 4+5R TCA AAA GCA AAG GAC CTT GAA 
6 6F TTG CTA AAA CTG CAA TGC AAA 
 6R TGT GTA CAA ACT TTA GGC AAG AGA A 
7 7F TGC CAA CCC TCT TGA AGT CT 
 7R GCT TCT GTT TTG TGG CGA AT 
8+9 8+9F GAA CTT TGA ATT ACC CTC TGT GC 
 8+9R TCA GAC ATC CCT TGT TTC ACC 
10 10F AGG ACA TTA GTA TCA GTG AGG ACA G 
 10R TTG GGG AAT TCA CTC CAG AC 
11-1 11-1F TGA ATG TTT GGA TAC TTA CCT CTG A 
 11-1R TCA CTC AAG ACT AGG CAC CTG A 
11-2 11-2F GCA TTG TAT TCA AAG TTG CAG TG 
 11-2R TGC TTT CAA AAC ACC AGT TCT T 
11-3 11-3F CAG ACC AGT TGC GCT GAT TA 
 11-3R TTG TAG GCA AAC ACA CCA TTG 
 
Primers for the RT-PCR 
 
Fragment Primer name 
F=forward 
R=reverse 
Primer Sequences 
1 1F GACTCTGCCCAGACTCTTCACT 
 1R GGTTCATGTAAAATCGATCCAA 
2 2F CCAGATGACCAGAAAGCATTATC 
 2R AATAATTCTCAGGGGAACACCA 
3 3F CAGTTGAACACCAGGAAAATCA 
 3R CACTGGTGTAGACCCACTTTGA 
 
2.2.3. Polymerase Chain Reaction 
 
The PCR is a process used to amplify a segment of DNA. It allows the generation of large amounts 
of DNA for sequencing and the analysis of genetic variations. It consists in a series of synthetic 
reactions. A synthetic reaction can be divided in three steps: denaturation, annealing and DNA 
chain extension. The reaction mixture is composed of forward and reverse primers, the four 
deoxynucleotids triphosphates (dNTPs) in excess, a buffer system and the Thermophilus 
Acquaticus (Taq) DNA polymerase. 
In the first step, the template DNA is denatured by heating. The double-stranded DNA becomes 
single-stranded. The reaction mix is then cooled. The primers can so anneal to their 
complementary sequences. The forward primer anneals to the 3’ terminus of the anti-sense strand 
and the reverse primer anneals to 3’ terminus of the sense strand. After having annealed to their 
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target sequences, the primers are extended with the Taq DNA polymerase. As the Taq DNA 
polymerase is a thermostable enzyme, it can survive the heat denaturation step. Moreover, 
annealing and extension can then be carried out at elevated temperatures. In this way, the result 
of the amplification reaction is improved.  
As the product of each cycle is used as template for the next one, the amount of DNA doubles at 
each cycle. The DNA chains produced by the first cycles of amplification are heterogeneous in size. 
However, the segment between the two primers is preferentially amplified and will become 
dominant (21). 
 
PCR protocol 
 
The PCR for fragment 1 was carried out at a volume of 24 l with the following components: 
 
 4.8 l of DNA at a concentration of 20 ng/ l 
 
 12 l of Premix Fail Safe Buffer J  (Epicentre Biotechnologies) 
 
 1.92 l of forward primer at a concentration of 50 ng/ l 
 
 1.92 l of reverse primer at a concentration of 50 ng/ l 
 
 0,39 l Expand Long Template (Roche) 
 
 2.97 l of H2O 
 
PCRs for fragments 2 to 11-3 were carried out at a volume of 25 l with the following components: 
 
 5 l of DNA at a concentration of 20 ng/ l 
 
 12,5 l of Taq PCR Master Mix kit 250U from Qiagen. The Taq PCR Master Mix is a solution 
containing Taq DNA Polymerase, PCR Buffer, and dNTPs. 
 
 0,75 l of forward primer at a concentration of 50 ng/ l 
 
 0,75 l of reverse primer at a concentration of 50 ng/ l 
 
 6 l of H2O 
 
These components were mixed in reaction tubes. The PCR was performed in a Biometra 
thermocycler. The PCR programs chosen for our experiments are shown below. The annealing 
temperature was the same for exons 2 to 11 (54o) but it is different for exon 1 (61,2o).  
 
PCR program for Fragment 1 
 
Step 1 Step 2 Step 3 Step 4 Step 5 Step 6 
94o 94o 61,2o 72o 72o 4o 
10’ 30’’ 1’ 1’ 30’’ 7’ ∞ 
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The steps 2 to 4 were repeated 35 times. 
 
PCR program for Fragments 2 to 11-3 
 
Step 1 Step 2 Step 3 Step 4 Step 5 Step 6 
94o 94o 54o 72o 72o 4o 
10’ 30’’ 1’ 1’ 10’ ∞ 
 
The steps 2 to 4 were repeated 35 times. 
 
2.2.4. Agarose gel electrophoresis 
 
We performed an agarose gel electrophoresis to check the molecular size of the amplified DNA 
fragments. We wanted to know if the size in base pairs (bp) of the amplified DNA fragments 
corresponded to the calculated size of the DNA fragments we wanted to amplify, if the PCR 
product was clean enough (no smear) and if the amount of amplified DNA was sufficient to 
perform the sequencing reaction. 
 
Q-Biogene 2% agarose gel with GelRed preparation protocol 
 
The agarose gels were prepared by melting 3.2 g of Agarose TM Molecular-Biology Grade from Q-
Biogene in the presence of 160 ml of Tris-borate (TBE) 0.5x as buffer. The mix was heated in the 
microwave until the agarose dissolved and a transparent solution was achieved. When the mix had 
cooled down, we added 16 l of GelRed Nucleic Acid Gel Stain 10’000x in DMF 0.5 ml from 
Biotium. The GelRed is a fluorescent nucleic acid gel stain. The solution was then poured into a 
mold and allowed to harden. If the agarose gels were not used immediately, they were covered by 
plastic foil and stocked at 4oC. 
 
Electrophoresis procedure 
 
We mixed 4 l of PCR-product with 2 l of loading dye from Qiagen. The loading dye is a solution 
containing marker dyes. It allows the assessment of the DNA migration and it weighs down the 
DNA so that it sinks into the bottom of the wells. The gel must be submerged in the buffer. We 
then loaded the mixture into the slots of the gel using a micropipette. 1.3 l of GeneRuler® 
1000bp DNA ladder from Fermentas was loaded into the first slot. DNA ladder is a solution 
containing DNA molecules of different sizes. It is used as reference to evaluate the size of DNA 
fragments. We applied a tension of 135 V for 30 minutes. The DNA fragments migrated and were 
sorted by size in the electrical field. 
 
2.2.5. PCR purification 
 
The aim of a PCR purification is to desalte the PCR product and to remove excess dNTPs and 
primers.  
 
PCR purification protocol: 
 
 Add MilliQ H2O water in each reaction tube with PCR product to obtain a volume of 100 l. 
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 Load the 100 l in the multiscreen PCR 96 Filter Plate from Millipore. The multiscreen 
PCRm96 Filter Plate is composed of a size-exclusion membrane that allows the selective 
binding of DNA fragments. 
 
 Filter with Millipore Vacuum Mannifold for 5 to 10 minutes or until the wells are dry. The 
Millipore Vacuum Mannifold is a filtration system using vacuum. 
 
 Blot excess liquid from the bottom of the multiscreen PCRm96 Filter Plate on an absorbent 
material like Kimberly-Clark® KIMTECH® KimWipes. KimWipes are cleaning tissues. 
 
 Add 25 l of MilliQ H2O to each well. 
 
 Put the plate on the plate shaker for 10 to 15 minutes to resuspend the samples. 
 
 Purified PCR products are transfered in new reaction tubes. 
 
2.2.6. Sequencing Reaction 
 
We use the enzymatic method of DNA sequencing, which is the sequencing by chain termination. 
The principle of the sequencing reaction is the same as for the PCR. It also consists in three main 
steps: denaturation, annealing and DNA synthesis. The reaction mixture is composed of primers, 
dNTPs, Taq DNA polymerase and dideoxynucleoside triphosphates (ddNTPs). 
ddNTPs are analogues of normal dNTPs. However, they lack a hydroxyl-residue at the 3’ position of 
deoxyribose. DNA polymerases can incorporate them into a DNA chain through their 5’ 
triphosphate groups. But no phosphodiester bond can be formed with the next dNTP because of 
the lack of 3’-hydroxyl residue. The DNA chain cannot be extended. Competition between dNTPs 
and ddNTPs results in production of DNA fragments with different sizes. The size is determined by 
the distance between the primer and the site of premature termination. ddNTPs are fluorescently 
labelled. Each ddNTPs emits a different fluorescent color: ddATP green, ddCTP blue, ddGTP black, 
and ddTTP red (22). 
 
Sequencing reaction protocol: 
 
The sequencing reaction is carried out in a final volume of 5 l. The following components are 
required: 
 
 0.5-0.8 l of purified PCR products, the quantity of product depends on the intensity of the 
band obtained on the agarose gel after electrophoresis. 
 
 0.8 l of BigDye Terminator v.3.1/v.1.1 Ready Reaction Mix, part of the BigDye Terminator 
Cycle Sequencing Kit from Applied Biosystems. The BigDye Terminator v.3.1/v.1.1 Ready 
Reaction Mix is a solution containing the dye terminators. The dye terminators are the 
marked ddNTPs. 
 
 0.4 l of Buffer BigDye Terminator v.3.1/v.1.1 Sequencing 5x from Applied Biosystems. The 
buffer is a solution of Tris-HCL, pH 9.0 and MgCI2. It provides the pH and magnesium 
optimal for the reaction. 
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 0.8 l Oligo dNTPs (50 ng/ l) 
 
 0.8 l of forward or reverse primers. Two sequencing reactions will be run for each DNA 
fragments, one with the forward primer and the other with the reverse. We will obtain in 
this way the complete sequence of the DNA fragments. 
 
 2.2 to 2.5 l of H2O to obtain a final volume of 5 l. 
 
All these components are mixed together in tubes. Then the sequencing reaction is performed in a 
Biometra thermal cycler with the following program: 
 
Sequencing reaction program 
 
Step 1 Step 2 Step 3 Step 4 Step 5 Step 6 
96o 96o 50o 60o 4o 4o 
1’ 10’’ 5’ 4’ 7’ ∞ 
 
The steps 2 to 4 are repeated 25 times. 
 
2.2.7. Sequencing reaction purification 
 
The unincorporated dye terminators, excess dNTPs and contaminating salts must be removed to 
obtain high quality sequencing data. This increases the intensity of the fluorescence signal. 
 
Sequencing reaction purification protocol: 
 
 Add 20 l of injection solution in each reaction tube with 5 l of sequencing reaction 
product. 
 
 Transfer the 25 l in the SEQ96 plate from Millipore. The SEQ96 plate is composed of a 
size-exclusion membrane. 
 
 Filter with Millipore Vacuum Mannifold for 3 to 5 minutes or until the wells are dry. 
 
 Blot excess liquid from the bottom of the SEQ96 plate on an absorbent material 
(Kimwipes). 
 
 Add 25 l of injection solution to each well and repeat the vacuum step. 
 
 Blot excess liquid from the bottom of the SEQ96 plate on an absorbent material 
(Kimwipes). 
 
 Add 25 l of injection solution and put the plate on the plate shaker for 10 to 15 minutes to 
resuspend the samples. 
 
 Transfer the 25 l of purified sequencing reaction product in a sequencing plate. 
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 Add 5 l of HiDi-formamide in each sample to avoid the evaporation of the samples during 
the plate analysis in the sequencer. 
 
 
2.2.8. Sequencing on an ABI PRISM® 3100 Genetic Analyzer 
 
In the ABI PRISM® 3100 Genetic Analyzer, DNA fragments migrate through a capillary containing a 
polyacrylamide electrophoretic gel, where they are separated according to their size. This method 
is the DNA sequencing by capillary electrophoresis. In the capillary, DNA chains pass in front of a 
laser beam focused on a fixed position, which induces a distinct fluorescent signal depending on 
the ddNTPs. A computer analyzes the data and the sequence is visualized as alternating peaks of 
one of the ddNTPs colors, according to the nucleotides sequence of the DNA of interest (22). 
 
2.2.9. Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) 
 
The basic principle of RT-PCR is the same as for PCR starting from mRNA as template. The cDNA is 
synthesized by the enzyme reverse transcriptase (RT). The RT is an enzyme present in retroviruses 
that can synthesize DNA from RNA. The cDNA is single-stranded DNA that does not contain any 
introns and derives from a coding DNA segment (22). The obtained DNA was then purified and 
sequenced as described previously. 
 
RT-PCR protocol: 
 
For the RT-PCR the Qiagen one step RT-PCR kit was used. The reactions were carried out in a final 
volume of 20 l containing the following components: 
 
 2 l of RNA at a concentration of 20 ng/ l 
 
 4 l of Qiagen one step RT-PCR Buffer 5x. The buffer prevents inhibition of PCR 
amplification by reverse transcriptases, allows specific primer annealing over a wide range 
of temperatures and efficient RT-PCR from any RNA template. 
 
 0,8 l of dNTPs mix, 10mM each 
 
 1,8 l of forward primer and reverse primer at a concentration of 50 ng/ l  
 
 0,8 l of Qiagen one step RT-PCR Enzyme mix. The enzyme mix contains reverse 
transcriptases and Taq DNA polymerases for reverse transcription and PCR. The two 
reactions can efficiently occur in one tube. 
 
 1 l of Q-Solution 5x. The Q-Solution facilitates reverse transcription and amplification of 
GC-rich templates or those with a high degree of secondary structure. RT-PCR is then 
optimized for difficult templates. 
 
 7,8 l of RNA free water 
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The reactions were carried out in a Biometra thermocycler with the following program: 
 
RT-PCR program for fragments 1 to 3 
 
Step 1 Step 2 Step 3 Step 4 Step 5 Step 6 Step 7 
50o 95o 94o 58o 72o 72o 10o 
30’ 15’ 30’’ 30’’ 1’ 10’ ∞ 
 
The steps 3 to 5 are repeated 39 times. 
 
2.2.10. Nomenclature for the description of sequence variations at DNA level 
 
To describe the sequence variations of PDK4, we followed the guidelines of the Human Genome 
Variation Society (www.hgvs.org). The subsequent recommendations were taken from den 
Dunnen JT and Antonarakis SE (2000). Hum.Mutat. 15: 7-12. (23) 
 
The nucleotides are designated by the bases: A (adenine), C (cytosine), G (guanine) and T 
(thymidine).  
 
The nucleotide numbering is proceeded as follows:  
 There is no nucleotide 0.  
 The nucleotide 1 is the A of the ATG-translation initiation codon.  
 The nucleotide 5’ of the ATG-translation initiation codon is -1, the previous -2 and so on.  
 The nucleotide 3’ of the translation stop codon is *1, the next *2 and so on. 
 
The intronic nucleotides are described according to their position in the intron:  
 If the nucleotide is at the beginning of the intron, we use the number of the last nucleotide 
of the preceding exon, a plus sign and the position in the intron, like c.77+1G.  
 If the nucleotide is at the beginning of the intron, we use the number of the first nucleotide 
of the following exon, a minus sign and the position upstream in the intron, like c.78-1G. 
 In the middle of the intron, numbering changes from “c.77+…” to “c.78+…”. For introns 
with an uneven number of nucleotides, the central nucleotide is the last described with a 
plus sign. 
 
The sequence variations of PDK4 include substitutions, deletions, duplication and variability of 
short sequence repeats. They are described as follows: 
 Single nucleotide substitutions are designated by a “>”-character, indicating “changes to”. 
c.76A>C denotes that at nucleotide 76 an A is changed to a C. 
 Deletions are designated by “del” after an indication of the first and last nucleotide(s) 
deleted. c.7_8del or c.7_8delTG denotes a TG deletion in the sequence ACTTTGTGCC to 
ACTTTGCC. 
 Duplications are designated by “dup” after an indication of the first and last nucleotide(s) 
duplicated. c.7_8dup or c.7_8dupTG or c.7_8dup2 denotes a TG duplication in the 
sequence ACTTTGTGCC to ACTTTGTGTGCC. 
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 Variability of short sequence repeats are described as c.123+74T(3_6). c.123+74 indicates 
the start of the first nucleotide of the variable repeat and T indicates the sequence of the 
repeat unit. The underscore is used to indicate the range (3 to 6 times). 
 
 
3. RESULTS 
 
3.1 Review of the medical records of 10 IKH patients 
 
Ten patients with 24 IKH episodes were included in this study. The medical records of the patients 
were reviewed and each episode of IKH was characterized (see Methods).  
 
Clinical features  
 
1. Sex: 
Our group of patients is composed of five girls and five boys. The proportion of female and male is 
thus equal.  
 
2. Age of onset: 
The mean age at first crisis of our patient group was 37,5 months. 3 of our 10 patients had an age 
under 18 months (patients 3, 4 and 7) and 1 patient an age over 5 years (patient 6) when they 
presented with the first IKH at the hospital. 
 
Patient Sex IKH episode Age Height Weight Trigger 
 
1 M 1 4y 9m P10-25 P10-25 Appetite loss 
2 F 2.1 2y 5m P25-50 P3 Infection 
  2.2 2y 9m P25-50 P50 Febrile infection 
  2.3 3y 7m P50 P50 ? 
  2.4 3y 8m P75-90 P50 Febrile infection 
  2.5 3y10m ? P10-25 ? 
  2.6 4y10m ? P50 Fever 
  2.7 5y10m P50-75 P75-90 Infection 
  2.8 6y10m ? P25-50 Infection 
3 F 3.1 1y 4m P50-75 P25-50 Appetite loss 
  3.2 2y ? ? Infection 
4 M 4.1 1y4m P-50-75 P10 Appetite loss 
Infection 
  4.2 1y6m P3 P3-10 ? 
5 F 5.1 3y2m ? P25 Infection 
  5.2 3y2m ? P25 Infection 
6 F 6 10y11m P<3 P<3 Appetite loss 
7 M 7 1y2m ? ? Infection 
8 F 8.1 1y10m P50 P50-75 Appetite loss 
Infection 
  8.2 3y7m P75-90 P75-90 Appetite loss 
Infection 
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9 M 9 2y10m ? ? Appetite loss 
Infection 
10 M 10.1 1y6m ? ? Appetite loss 
Fever 
  10.2 1y11m ? P10 Appetite loss 
Fever 
  10.3 2y4m ? P3-10 Appetite loss 
Fever 
  10.4 6y3m P25-50 P3 Appetite loss 
Fever 
 
3. Weight and height: 
In our cohort we find 4 out of 7 patients (=57%, data missing for patients 5, 7 and 9) with a height 
below the 50th percentile corresponding to 5 out of 13 (=39%) IKH episodes (height not 
documented for 11 episodes). 7 out of 8 patients (=88%, data missing for patients 7 and 9) have a 
weight below the 50th percentile corresponding to 13 out of 20 (=65%) IKH episodes (weight not 
documented for 4 episodes).  
 
4. Diet, nutritional habits: 
The available information on our patient group revealed little appetite, frequent intake of small 
snacks (lack of structured meals allowing glycogen and fat storage) and a preference for high fat 
snacks that can favor ketosis. 
 
5. Triggers of hypoglycemic crises: 
The triggers of the crisis in the 24 documented IKH episodes were loss of appetite, fever and 
infection due to an intercurrent illness. These infections are predominantly gastroenteritis, rhinitis, 
bronchitis and pharyngitis. 
 
6. Symptoms of hypoglycemic crises: 
The symptoms of hypoglycemia presented by our patients were vomiting, nausea, pallor, tremor, 
hypotonia, sleepiness, fatigue, decreased energy, apathy, altered level of consciousness, loss of 
consciousness and seizures. The most frequent symptom presented by our patients was vomiting. 
Lethargy presented as sleepiness, fatigue, decreased energy, apathy, altered level of 
consciousness and loss of consciousness was also a frequent symptom among our patients.  
Patients 1, 2, 3, and 9 presented neurovegetative and neuroglycopenic symptoms. Patient 2 only 
showed symptoms of neuroglycopenia at one of the eight reported crisis. Patient 3 had no 
autonomic response before lethargy at the second crisis. Patients 4 and 7 did not show any 
neurovegetative symptoms, while patients 5 and 10 did not show any neuroglycopenic symptoms. 
Patient 8 had one episode with only autonomic response and a second episode during which he 
presented both kinds of symptoms.  
A blood glucose level of 1.8 mmol/l is the lowest value documented among our data. With the 
same blood glucose, patient 1 presented seizures and loss of consciousness, patient 4 had an 
altered level of consciousness whereas patient 2 only presented vomiting and nausea.  
 
7. Varia: 
No hepatomegaly or delayed psychomotor development has been reported in our patient cohort.  
 
Biochemical features 
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Levels of pyruvate, lactate, lactate/pyruvate, -hydroxybutyrate and acetoacetate in blood can 
only be determined in a medical center with a specialized laboratory, like the CHUV. The blood 
samples must be analyzed as quickly as possible to determine these values. This explains why 
these levels are often not available for our patients as most episodes of hypoglycemia were 
treated in regional hospitals.  
1. Blood glucose: 
Documented blood glucose levels of our patients ranged from 1.8 to 5.4 mmol/l.  
 
2. Lactate and pyruvate: 
Two pyruvate values were available for patient 8 and both were slightly elevated. Lactate levels 
were normal for patients 1, 2, 3, 8 and 10. Patient 4 had the first time a normal lactate level and 
during another crisis a slightly elevated lactate at 3 mmol/l. This could be an artifact due to a 
difficult blood take. The lactate/pyruvate ratio could only be calculated for the two IKH episodes of 
patient 8 and were normal. 
 
3. Keton bodies in blood and urine strip tests: 
-hydroxybutyrate and acetoacetate values were only available for patient 8. During one crisis, 
both values were elevated and during another one, only the acetoacetate level was elevated. 
Urine test strips were negative for keton bodies in patient 8 (timepoint of urine collection?), but 
most patients showed +++ or ++++. 
 
4. Free fatty acids (FFA): 
FFA levels have only been documented in 5 episodes. They were elevated in patients 1, 3 and 4. 
Patient 8 had one normal and one elevated measurement.  
 
5. Plasma amino acids: 
Patient 4 did not show any significant alteration of amino acid profile in plasma. Patient 1 had an 
elevated level of leucine and isoleucine. Patients 2, 3 and 5 had increased levels of leucine, 
isoleucine and valine. Patients 6 and 9 had elevated levels of glutamine. Patient 8 had once 
increased values of glutamine, proline, alanine, valine and leucine and once elevated levels of 
glutamine, proline, alanine and taurine. Patient 10 had elevated levels of glutamine, alanine, 
threonine, serine, lysine and glycine, but the blood was not taken during an IKH episode. The 
changes in amino acid profiles of patients 6, 8, 9 and 10 might be of nutritional origin. No amino 
acid analysis was available for patient 7. 
 
6. Free and total carnitine/acylcarnitine profile: 
Data on total and free carnitine levels were available for 5 out of 10 patients. They were normal 
for patients 2, 3 and 5, increased for patient 6 and decreased for patient 9. Free carnitine levels 
were normal for patient 5, increased for patient 6 and decreased for patients 2, 3 and 9. For 
exclusion of a primary carnitine deficiency, levels of free carnitine were controlled in patients 2, 3 
and 9 after the IKH episode. Nearly all patients had altered acylcarnitines profiles compatible with 
ketosis and lipolysis, but without signs indicating a primary metabolic disorder. Only patient 9 had 
a normal acylcarnitine profile, whicht could be explained by a low total carnitine level at this 
moment.  
 
7. Plasma transaminases: 
Data on plasma transaminases was available in 6 out of 10 patients (not documented for patients 
4, 5, 7 and 8). ASAT was increased for patients 3 and 10 and normal for patients 1, 2, 6 and 9. ALAT 
value was normal for all 6 patients.  
24 
 
8. Cortisol, insulin, IGF1 and IGFBP-3: 
Patients 1, 3, 4, and 7 had elevated levels of cortisol while patients 9 and 10 had levels in the 
normal range. Cortisol was not documented for patients 2, 5, 6 and 8. Insulin levels have been 
determined in only 4 patients. It was normal in patients 3 and 4 and decreased in patients 1 and 7. 
IGF-1 has been measured in patient 1 (normal) and patient 7 (decreased). IGFBP-3 levels were 
available for patients 1, 4 and 7 with a normal result in all of them. 
 
9. Urinary organic acids: 
Available data concerning patients 1 and 7 are limited. All others patients present ketonuria, 
dicarboxyluria, 3-OH-dicarboxyluria and lactaciduria at various degrees of severity. The two crises 
of patient 8 had different urinary organic acids profiles: low or normal ketonuria, dicarboxyluria 
present or not, but no lactaciduria. Patient 3 also had various profiles: the dicarboxyluria and 3-
OH-dicarboxyluria were one time important compared to the ketosis and the other time they were 
only mild. However, patient 10 had several similar profiles. In patients 4, 8 and 10 other 
pathological organic acids were also present during an IKH episode, but were not detectable in 
control samples.  
 
3.2 DNA sequencing 
 
The genomic DNA of our ten IKH patients and of a control (Co) was sequenced according to the 
methods described in the previous chapter. The ten patients were numbered from 1 to 10 to 
guarantee the confidentiality and interpretation of results independently from the clinical 
presentation. The results of sequence analysis are summarized in the following tables and in 
Figure 3. Polymorphisms already described in the literature are written in blue. 
 
Substitution, duplication, deletion and variability of short sequence repeat were found. Patients 1 
and 4 had no special features in their PDK4 sequences. No changes have been revealed in 
fragments 3 and 7. 
 
 
 
 
Figure 3: Results of PDK4 gene sequencing 
 
 
In fragment 1, five substitutions and a CT-duplication are located upstream the ATG-translation 
initiation codon. All patients were heterozygous for those variations. These changes were also 
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found in the control DNA, except the c.-184T>C and the c.-68G>C. The findings c.-184T>C, c.-183_-
182dupCT and c.-126A>G are known polymorphism, the others not. 
 
Only patient 10 had the c.131-86_131-85delTG in the intron 2. The patient was heterozygous for 
this deletion which was not present in the control DNA and is not a known polymorphism. 
 
Patient 3 is heterozygous for a stretch of eight T-residues instead of nine T-residues in intron 4. 
This variable stretch was not found in the control DNA and is not a known polymorphism. 
 
In fragment 6, a G to A substitution located in intron 6 was detected in patients 2, 3, 5, 6, 8, 9, 10 
and the control DNA. This polymorphism has not yet been described. Patient 3 was homozygous 
for this variation, while the other patients were heterozygous. 
 
Intron 8 of patients 3 and 10 contained a C to T substitution and intron 9 of patient 7 revealed a G 
to A substitution. Both substitutions were not found in the control DNA and are not known as 
polymorphisms. Patients were all heterozygous for these changes. 
 
A C to T and a A to C substitution were found in exon 10. A T to C substitution was located in 
intron 10. The c.996C>T is a known polymorphism. The other changes have not been described as 
polymorphisms. Patient 10 was homozygous for these variations, the other patients were 
heterozygous. 
 
Changes found in fragments 11-1, 11-2 and 11-3 are all located downstream the TGA-translation 
stop codon and are known polymorphisms, except c.*2148G>A. Patients 3 and 10 were 
homozygous for those variations, the other patients were heterozygous.  
 
Results for fragments 1 to 4+5 
 
 Fragment 1 Fragment 2 Fragment 3 Fragment 4+5 
1 - - - - 
2 
c.-376T>C 
c.-308A>G 
c.-183_-182dupCT 
c.-126A>G 
heterozygous 
- - - 
3 
c.-376T>C 
c.-308A>G 
c.-184T>C 
c.-183_-182dupCT 
c.-126A>G 
heterozygous 
- - 
c.530-27T(8_9) 
heterozygous 
4 - - - - 
5 
c.-376T>C 
c.-308A>G 
c.-184T>C 
c.-183_-182dupCT 
c.-126A>G 
heterozygous 
- - - 
6 c.-376T>C - - - 
26 
c.-308A>G 
c.-184T>C 
c.-183_-182dupCT 
c.-126A>G 
c.-68G>C 
heterozygous 
7 - - - - 
8 
c.-376T>C 
c.-308A>G 
c.-184T>C 
c.-126A>G 
heterozygous 
- - - 
9 
c.-376T>C 
c.-308A>G 
c.-183_-182dupCT 
c.-126A>G 
heterozygous 
- - - 
10 
c.-376T>C 
c.-308A>G 
c.-184T>C 
c.-183_-182dupCT 
c.-126A>G 
heterozygous 
c.131-86_131-
85delTG 
heterozygous 
- - 
Co 
c.-376T>C 
c.-308A>G 
c.-183_-182dupCT 
c.-126A>G 
heterozygous 
- - - 
 
Results for fragments 6 to 10 
 
 Fragment 6 Fragment 7 Fragment 8+9 Fragment 10 
1 - - - - 
2 
c.694+31G>A 
heterozygous 
- - 
c.1023A>C 
c.1095+60T>C 
heterozygous 
3 
c.694+31G>A 
homozygous 
- 
c.870+12C>T 
heterozygous 
c.996C>T 
c.1023A>C 
c.1095+60T>C 
heterozygous 
4 - - - - 
5 
c.694+31G>A 
heterozygous 
- - 
c.1023A>C 
c.1095+60T>C 
heterozygous 
6 
c.694+31G>A 
heterozygous 
- - 
c.1023A>C 
c.1095+60T>C 
heterozygous 
7 - - c.981+33G>A - 
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heterozygous 
8 
c.694+31G>A 
heterozygous 
- - 
c.1023A>C 
c.1095+60T>C 
heterozygous 
9 
c.694+31G>A 
heterozygous 
- - 
c.1023A>C 
c.1095+60T>C 
heterozygous 
10 
c.694+31G>A 
heterozygous 
- 
c.870+12C>T 
heterozygous 
c.1023A>C 
c.1095+60T>C 
homozygous 
Co 
c.694+31G>A 
heterozygous 
- - 
c.1023A>C 
c.1095+60T>C 
heterozygous 
 
Results for fragments 11-1 to 11-2 
 
 Fragment 11-1 Fragment 11-2 Fragment 11-3 
1 - - - 
2 
c.*42A>G 
c.*295A>C 
c.*343delA 
heterozygous 
c.*1000T>G 
c.*1251C>T 
heterozygous 
c.*1894C>T 
c.*2051A>T 
heterozygous 
3 
c.*343delA 
homozygous 
c.*1000T>G 
c.*1251C>T 
homozygous 
c.*1894C>T 
c.*2051A>T 
homozygous 
4 - - - 
5 - 
c.*1000T>G 
heterozygous 
- 
6 
c.*343delA 
heterozygous 
c.*1000T>G 
c.*1251C>T 
heterozygous 
c.*1894C>T 
c.*2051A>T 
heterozygous 
7 - - - 
8 
c.*343delA 
heterozygous 
c.*1000T>G 
c.*1251C>T 
heterozygous 
c.*1894C>T 
c.*2051A>T 
heterozygous 
9 
c.*42A>G 
c.*295A>C 
c.*343delA 
heterozygous 
c.*1000T>G 
c.*1251C>T 
heterozygous 
c.*1894C>T 
c.*2051A>T 
heterozygous 
10 
c.*343delA 
homozygous 
c.*1000T>G 
c.*1251C>T 
homozygous 
c.*1894C>T 
c.*2051A>T 
c.*2148G>A 
homozygous 
Co 
c.*343delA 
heterozygous 
c.*1000T>G 
c.*1251C>T 
heterozygous 
c.*1894C>T 
c.*2051A>T 
heterozygous 
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3.3 cDNA sequencing 
 
In patients 1, 2, 3 and 6 cultivated fibroblasts deriving from a former skin biopsy were available for 
RNA extraction. As previously explained, RNA was extracted from fibroblasts and cDNA was 
obtained by RT-PCR. Two transcripts of PDK4 are described (PDK4-001 and PDK4-201). We 
sequenced the longer transcript (PDK-001, ENST00000005178) of patients 1, 2, 3 and 6 and the 
control in order to examine if the variations found by DNA sequencing affect protein synthesis. 
 
In fragment 1 of the cDNA, a G to C substitution located upstream the ATG-translation initiation 
codon has been found in patient 6 and the control. 
 
The sequencing of fragment 2 did not reveal any sequence alteration.  
 
Patient 3 had a known polymorphism in fragment 3. Patients 2, 3 and 6 had a A to C substitution. 
The codon GCA becomes GCC. However, this does not lead to an amino acid change. Both codons 
are coding for an alanine. 
 
Results for fragments 1 to 3 
 
 Fragment 1 Fragment 2 Fragment3 
1 - - - 
2 - - c.1023A>C 
3 - - 
c.996C>T 
c.1023A>C 
6 c.-68G>C - c.1023A>C 
Co c.-68G>C - c.1023A>C 
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4. DISCUSSION 
 
IKH is defined by episodes of hypoglycemia with presence of ketone bodies in plasma and urine, 
provoked by periods of starvation, often in combination with an intercurrent illness (2). 
PDK4 phosphorylates and inactivates the PDC to conserve glucose when glucose supply is lacking 
during fasting (10). The PDK4 gene has be selected for our Master project because current 
knowledge supports its central role in glucose homeostasis in fasting and fed states. 
 
The analysis of clinical data of our patients mostly confirms the features of IKH reported in the 
literature. Children with IKH were reported to be predominantly male. In our study with a very 
small patient group we find an equal relation between both genders. Regarding larger patient 
groups, IKH rarely begins before the age of 18 months or after the age of 5 years (3). This disorder 
typically spontaneously remits by the age of 8 or 9 years (1). In our cohort, the mean age at first 
crisis is 37,5 months. This value is situated between the age of presentation and the age of 
remission of IKH. However, we find 3 out of 10 patients with a first crisis before the age of 18 
months and one patient beyond the age of 5 years (= 40% of initial presentation outside the 
reported range). Children with IKH often have a height and weight below the 50th percentile for 
age (3). In our cohort this seems to be particularly true for the weight with 88% of documented 
patients below the average weight for age in contrast to only 57% of patients with a height below 
average. This supports the hypothesis of low availability of gluconeogenetic substrates. The type 
of diet could be a precipitating factor for hypoglycemia. Frequent fat rich little snacks were 
dominating in our patients thus supporting the production of ketone bodies. Intercurrent illnesses, 
particularly infections of the upper airways and gastroenteritis, are frequently the trigger of an IKH 
episode accompanied by vomiting and lethargy. For the same level of glycemia, one patient only 
presents autonomic response and the other presents directly neuroglycopenic symptoms. With 
repeated or prolonged episodes of hypoglycemia, the threshold of neurovegetative symptoms is 
decreased to that for neuroglycopenic signs. Besides that, patients might have individual 
thresholds. Some patients present mainly with symptoms of autonomic response during 
hypoglycemia, some others mainly with neuroglucopenic symptoms.  
 
The biochemical phenotype of our group of patients was quite homogeneous: low blood glucose, 
high blood/urine ketones, moderate and usually comptensated metabolic acidosis, appropriate 
increase of contro-insular hormones with suppressed insulin, absence of pathologic metabolites in 
urine indicating the absence of an underlying aminoacidopathy or organic aciduria. Some patients 
showed, beside ketosis, a significant increase of dicarboxylic acids in urine. These metabolites 
witness the activation of alternative (microsomal) fatty acid oxidation when mitochondrial fatty 
acid oxidation is saturated by an intense lipolysis. The extent of dicaboxilic aciduria varied 
between patients, with no correlation with severity of symptoms and/or level of glycemia. Some 
of the reported IKH episodes showed results that were not conform to this biochemical 
phenotype. In these cases it seems to be most likely that blood and/or urine sampling has not 
been performed during hypoglycemia. Hypoglycemia is an emergency. Children with severe 
presentation of hypoglycemia often receive intravenous glucose even before blood is taken. This 
explains documentation of normal glycemia, lack of ketone bodies, not suppressed insulin levels 
and not elevated cortisol values. 
 
The sequencing of PDK4 gene in genomic DNA has shown multiple changes. The majority of them 
are known polymorphisms and/or are also found in the control DNA. The variations that are not 
known polymorphism or not found in the control DNA are mostly situated in introns, upstream the 
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ATG translation start codon or downstream the translation stop codon. They are not predicted to 
interact with the gene transcription or translation. Unlike intronic variations, exonic changes may 
affect the protein synthesis. However, the exonic changes found in PDK4 are known 
polymorphisms also present in controls or do not lead to an amino acid change in the protein. 
Thus, they do not seem to be pathogenic. However, to be sure that intronic changes did not 
generate splicing errors, we sequenced the cDNA. Only fibroblasts of patients 1, 2, 3 and 6 were 
available. The sequencing of the longer PDK4 transcript has not revealed any altered cDNA form. 
Variations of PDK4 sequence found in patients and in the control DNA are probably not yet 
described polymorphisms of the PDK4 gene. Because of their presence in controls with no IKH, 
they are not supposed to affect PDK4 activity. 
 
This study has certainly some limitations: a) the size of the patient group is small, not allowing any 
statistical analysis of the clinical and biochemical parameters analyzed; b) biochemical data were 
not complete at each episode of hypoglycemia in each patient, because hypoglycemic episodes 
took place at different moments in different hospitals; c) the study is retrospective and data were 
not collected with a well defined protocol.  
 
Conclusions 
 
IKH is the most common cause of hypoglycemia in children between 1 and 5 years of age among 
non-diabetic children. It is a cause of multiple hospitalisations and of extensive investigations in 
affected children. IKH has a potential risk for life threatening events if not treated promptly. Given 
the frequency and the observation of heritability of this condition, more research effort should be 
done in understanding the molecular and biochemical basis of this benign, but potentially 
dangerous condition. 
No pathogenic changes in the open reading frame of PDK4 related to IKH were found in our 
cohort. However, our study has not completely excluded a possible role of the PDK4 gene in the 
pathogenesis of IKH. Further work should concentrate on the promoter of the PDK4 gene. Recent 
studies have shown that mutations on the PDK4 promoter affect the regulation of PDK4 gene 
expression (15–20). The other PDK isoforms could also be worth to be investigated. 
Even with the mentioned limitation of our study, our results seem to show no correlation between 
the clinical presentation, the biochemical features and the changes in PDK4 sequence.  
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